Associations of Height With the Risks of Colorectal and Endometrial Cancer in Persons With Lynch Syndrome

Jesca G M Brouwer, Polly A Newcomb, Tanya M Bisseling, Jane C Figueiredo, John L Hopper, Mark A Jenkins, Jan J Koornstra, Noralane M Lindor, Hans F A Vasen, Aung K Win, Ellen Kampman, Fränzel J B van Duijnhoven, Jesca G M Brouwer, Polly A Newcomb, Tanya M Bisseling, Jane C Figueiredo, John L Hopper, Mark A Jenkins, Jan J Koornstra, Noralane M Lindor, Hans F A Vasen, Aung K Win, Ellen Kampman, Fränzel J B van Duijnhoven

Abstract

People with Lynch syndrome (LS), who carry a pathogenic mutation in a DNA mismatch repair gene, have increased risks of colorectal cancer (CRC) and endometrial cancer (EC). A high reported variability in cancer risk suggests the existence of factors that modify cancer risk for persons with LS. We aimed to investigate the associations between height and CRC and EC risk for persons with LS using data from 2 large studies. Information on 1,115 men and 1,553 women with LS from the Colon Cancer Family Registry (1998-2007) and the GEOLynch Cohort Study (2006-2017) was harmonized. We used weighted Cox proportional hazards regression models with age on the time axis to estimate adjusted hazard ratios and 95% confidence intervals for each 5-cm increment in self-reported height. CRC was diagnosed in 947 persons during 65,369 person-years of observation, and 171 women were diagnosed with EC during 39,227 person-years. Height was not associated with CRC for either men (per 5-cm increment, hazard ratio (HR) = 1.00, 95% confidence interval (CI): 0.91, 1.11) or women (per 5-cm increment, HR = 1.01, 95% CI: 0.92, 1.11), nor was height associated with EC (per 5-cm increment, HR = 1.08, 95% CI: 0.94, 1.24). Hence, we observed no evidence for an association of height with either CRC or EC among persons with LS.

Keywords: Lynch syndrome; body height; colorectal cancer; endometrial cancer; hereditary cancer; mismatch repair; weighted cohort.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

References

    1. Peltomäki P. Lynch syndrome genes. Fam Cancer. 2005;4(3):227–232.
    1. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12(1):49–55.
    1. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–5788.
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
    1. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004;126(1):42–48.
    1. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol. 2012;30(35):4409–4415.
    1. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34(3):490–497.
    1. ten Broeke SW, Brohet RM, Tops CM, et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2015;33(4):319–325.
    1. South CD, Hampel H, Comeras I, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100(4):277–281.
    1. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30(9):958–964.
    1. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Can Epidemiol Biomarkers Prev. 2014;23(3):437–449.
    1. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–1795.
    1. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer. 2013;12(2):229–240.
    1. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer. 2005;4(3):233–237.
    1. Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev. 2001;23(2):313–342.
    1. World Cancer Research Fund/American Institute for Cancer Research . Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. The Third Expert Report. Hyattsville, MD: National Center for Health Statistics; 2018.
    1. Abar L, Vieira AR, Aune D, et al. Height and body fatness and colorectal cancer risk: an update of the WCRF-AICR systematic review of published prospective studies. Eur J Nutr. 2018;57(5):1701–1720.
    1. Aune D, Navarro Rosenblatt DA, Chan DS, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015;26(8):1635–1648.
    1. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006;106(1):87–94.
    1. Meijer TW, Hoogerbrugge N, Nagengast FM, et al. In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology. 2009;55(4):414–422.
    1. Shiovitz S, Copeland WK, Passarelli MN, et al. Characterisation of familial colorectal cancer type X, Lynch syndrome, and non-familial colorectal cancer. Br J Cancer. 2014;111(3):598–602.
    1. Shashidharan M, Smyrk T, Lin KM, et al. Histologic comparison of hereditary nonpolyposis colorectal cancer associated with MSH2 and MLH1 and colorectal cancer from the general population. Dis Colon Rectum. 1999;42(6):722–726.
    1. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14(8):16365–16385.
    1. Ketabi Z, Bartuma K, Bernstein I, et al. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 2011;121(3):462–465.
    1. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008;26(36):5965–5971.
    1. Gylling A, Abdel-Rahman WM, Juhola M, et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut. 2007;56(7):926–933.
    1. Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology. 2005;128(3):590–599.
    1. Jӧnsson JM, Bartuma K, Dominguez-Valentin M, et al. Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. Fam Cancer. 2014;13(4):537–545.
    1. Campbell PT, Cotterchio M, Dicks E, et al. Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. Can Epidemiol Biomarkers Prev. 2007;16(9):1735–1744.
    1. Botma A, Nagengast FM, Braem MG, et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch Cohort Study. J Clin Oncol. 2010;28(28):4346–4353.
    1. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2331–2343.
    1. Jenkins MA, Win AK, Templeton AS, et al. Cohort profile: the Colon Cancer Family Registry Cohort (CCFRC). Int J Epidemiol. 2018;47(2):387–388i.
    1. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29(1):1–11.
    1. Rogers WH. Regression standard errors in clustered samples. Stata Tech Bull. 1993;3(13):19–23.
    1. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56(2):645–646.
    1. Bordini B, Rosenfield RL. Normal pubertal development: part II: clinical aspects of puberty. Pediatr Rev. 2011;32(7):281–292.
    1. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37–48.
    1. Møller P, Seppälä T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the Prospective Lynch Syndrome Database. Gut. 2017;66(9):1657–1664.
    1. Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306–1316.
    1. Spencer EA, Appleby PN, Davey GK, et al. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4):561–565.
    1. Connor Gorber S, Tremblay M, Moher D, et al. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obes Rev. 2007;8(4):307–326.
    1. Sorkin JD, Muller DC, Andres R. Longitudinal change in height of men and women: implications for interpretation of the body mass index. The Baltimore Longitudinal Study of Aging. Am J Epidemiol. 1999;150(9):969–977.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅